ceritinib and other second generation alk inhibitors for acquired resistance in alk-positive nsclc
Published 8 years ago • 249 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
3:44
alk inhibitors for acquired resistance: zykadia and alectinib
-
4:14
should a second generation alk inhibitor be first line therapy for patients with alk-positive nsclc?
-
2:20
timing of second generation alk inhibitors: first line vs. treatment after acquired resistance
-
2:52
understanding acquired resistance in alk lung cancer
-
4:44
are there clinically significant differences among the second generation alk inhibitors?
-
4:50
pennell new options in acquired resistance for alk positive non-small cell lung cancer (nsclc)
-
4:58
how do the new alk inhibitor drugs compare to xalkori (crizotinib) for alk lung cancer patients?
-
5:52
alk positive forum disease progression xalkori
-
22:46
mechanisms of alk resistance & implications for treatment
-
9:59
case based panel discussions - alk positive, developing resistance to alk inhibitors and next steps
-
2:30
cns disease in alk-positive nsclc: monitoring and systemic vs. radiation therapy
-
19:47
alk positive forum next generation inhibitors
-
1:23
ascend-1 and ascend-2: ceritinib for alk-rearranged nsclc and baseline brain metastases
-
31:43
new ideas and new treatment options for acquired resistance for alk/ros1
-
5:45
asco highlights, pt 10: after resistance to crizotinib in alk-positive advanced nsclc
-
29:51
current & emerging approaches to acquired resistance for alk/ros1
-
3:06
2020 ttf alk session qa panel progression on 2nd-gen alk inhibitor if biopsy shows no alk mutation
-
26:56
gracecast-085_lung-cancer_alk inhibition: who to screen and options for alk-positive patients
-
2:39
grace targeted therapies lung cancer 2021 - return to alectinib -progression on lorlatinib in alk